1. From Conference to the Clinic

2. Goals of this Program

5. New Information Regarding New Antidepressants: Vilazodone, Levomilnacipran, and Vortioxetine

6. SSRI-Associated Treatment Emergent Sexual Dysfunction After Switch to Vortioxetine or Escitalopram

7. SSRI-Associated TESD After Switch to Vortioxetine or Escitalopram

8. Post Hoc Analyses of Suicidality in Clinical Trials of Vilazodone

9. Suicidality in Clinical Trials of Vilazodone

10. Levomilnacipran ER Treatment in Adult MDD Patients With First-episode, Highly Recurrent, and Chronic MDD

11. Levomilnacipran ER (cont)

13. From Conference to the Clinic

14. Investigational SGAs as Adjunctive Treatment for MDD

15. Long-term Safety of Adjunctive Brexpiprazole (OPC-34712) in MDD: Results From 2 52-Week Open-label Studies

16. Long-term Safety of Adjunctive Brexpiprazole (OPC-34712) in MDD: Results From 2 52-Week Open-label Studies

17. Long-term Safety of Adjunctive Brexpiprazole (OPC-34712) in MDD: Results From 2 52-Week Open-label Studies (cont)

18. Efficacy and Safety of Cariprazine as Adjunctive Therapy in MDD A Double-blind, Randomized, Placebo-controlled Study

19. Efficacy and Safety of Cariprazine as Adjunctive Therapy in MDD: A Double-blind, Randomized, Placebo-controlled Study

20. Efficacy and Safety of Cariprazine as Adjunctive Therapy in MDD: A Double-Bblind, Randomized, Placebo-controlled Study

22. From Conference to the Clinic

23. EXPLORATION OF MECHANISMS OF ACTION AND A NEW CATEGORY OF MDD

24. Patterns of Antidepressant Efficacy With Quetiapine XR as Adjunct to Different Ongoing Antidepressants; Exploration of MOA Hypotheses: Study Design

25. Patterns of Antidepressant Efficacy With Quetiapine XR as Adjunct to Different Ongoing Antidepressants; Exploration of MOA Hypotheses: Results

26. Lurasidone For the Treatment of MDD With Mixed Features: A Randomized, Double-blind, Placebo-controlled 6-Week Trial: Study Design

27. Lurasidone For the Treatment of MDD With Mixed Features: A Randomized, Double-blind, Placebo-controlled 6-Week Trial: Results

29. From Conference to the Clinic

30. OTHER MODALITIES, OTHER TARGETS

31. Facing Depression Using Botulinum Toxin Update and Pooled Analysis from Clinical Trials: Study Design

32. Facing Depression Using Botulinum Toxin Update and Pooled Analysis from Clinical Trials: Results

33. A Randomized, Placebo-controlled Study of Bright Light Therapy, Fluoxetine, and the Combination, for Nonseasonal Major Depression: Study Design

34. A Randomized, Placebo-controlled Study of Bright Light Therapy, Fluoxetine, and the Combination, for Nonseasonal Major Depression

35. Effect of Vortioxetine on Cognitive Dysfunction in Subgroups of Adult MDD Patients: Study Design

36. Effect of Vortioxetine on Cognitive Dysfunction in Subgroups of Adult MDD Patients: Results

37. Abbreviations

38. Abbreviations (cont)

39. References

40. References (cont)

41. References (cont)

42. References (cont)

43. References (cont)